SCHEMBL2017025

SCHEMBL2017025

Cc1cc(O)ccc1-c1nnc(N(C)C2CCCc3ccccc32)c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 1/20 0.38
XBP1 P17861 1/20 0.38
HTT P42858 1/20 0.38
SPR P35270 1/20 0.35
TAS1R3 Q7RTX0 3/20 0.34
TAS1R1 Q7RTX1 3/20 0.34
PFKFB3 Q16875 2/20 0.34
TAS1R2 Q8TE23 2/20 0.34
PER2 O15055 1/20 0.33
CRY1 Q16526 1/20 0.33
CRY2 Q49AN0 1/20 0.33
ESR2 Q92731 2/20 0.33
ESR1 P03372 1/20 0.33
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
P4HB P07237 1/20 0.31
ATM Q13315 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019380 0.97 RAB9A (0.36) RAB9AALDH1A1XBP1HTTSPR
SCHEMBL2019595 0.94 MAOA (0.35) RAB9ASPRPER2CRY1CRY2
SCHEMBL2019391 0.82 ALDH1A1 (0.38) RAB9AALDH1A1XBP1HTTSPR
SCHEMBL12574543 0.81 ALDH1A1 (0.40) RAB9AALDH1A1XBP1HTTTAS1R3
SCHEMBL2022299 0.81 ALDH1A1 (0.40) RAB9AALDH1A1XBP1HTTTAS1R3
SCHEMBL2021567 0.80 TYR (0.42) ALDH1A1ESR2ESR1MEN1KMT2A
SCHEMBL2020824 0.79 ALDH1A1 (0.35) RAB9AALDH1A1XBP1HTTSPR
SCHEMBL2024607 0.75 MAOA (0.38) ALDH1A1XBP1HTTSPRPER2
SCHEMBL2014674 0.72 CRHR1 (0.40) KMT2AATMTSHR
SCHEMBL2017611 0.71 S1PR1 (0.42) ALDH1A1ESR2ESR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 RAB9A 2769/4885ALDH1A1 403/4885XBP1 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.